Use of sodium crotonate for preparing a medicine for treating ulcerative colitis
By formulating sodium crotonate into a pharmaceutically acceptable solid or semi-solid dosage form for the treatment of ulcerative colitis, the problem of the lack of effective therapeutic drugs in the prior art has been solved, and significant therapeutic effects on ulcerative colitis have been achieved.
Patent Information
- Application Number
- CN202310878199.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-18
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-07-18
AI Technical Summary
There are currently no reports of sodium crotonate being used to treat ulcerative colitis, and there is a lack of effective treatment drugs.
Sodium crotonate is used as the active ingredient to formulate pharmaceutically acceptable solid or semi-solid dosage forms, such as tablets, capsules, and injections, for the treatment of ulcerative colitis.
Sodium crotonate significantly improved the disease activity index, colon length, and pathological tissue score in mice with ulcerative colitis, demonstrating a significant therapeutic effect. It also regulated serum cytokine levels and alleviated inflammation.
Smart Images

Figure CN116650458B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine and relates to use of sodium crotonate for preparing a medicine for treating ulcerative colitis. Background Art
[0002] Ulcerative colitis (UC), also known as chronic nonspecific ulcerative colitis or idiopathic ulcerative colitis, is a common chronic intestinal disease and a multifactorial, multi-level nonspecific inflammation with unknown causes. The lesions are mainly in the mucosa and submucosa of the colon, with a continuous diffuse distribution, and most of them involve the rectum and sigmoid colon. The main clinical manifestations are abdominal pain, diarrhea, mucus, pus and blood in the stool, tenesmus, etc. Some patients have extraintestinal manifestations, such as joint, hepatobiliary diseases, and eye and skin injuries; the course of the disease is prolonged and the severity varies; the age of onset is mainly between 20 and 50 years old, but there is no significant gender difference. Epidemiological statistics at home and abroad show that the incidence and prevalence of UC have shown a significant upward trend. It is listed as one of the modern intractable diseases by the World Health Organization. Its etiology, pathogenesis and therapeutic drugs have always been a hot topic of research.
[0003] There are currently no reports on the use of sodium crotonate in the treatment of UC. Summary of the invention
[0004] The purpose of the present invention is to provide a use of sodium crotonate for preparing a medicine for treating ulcerative colitis.
[0005] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0006] The invention discloses a use of sodium crotonate for preparing a medicine for treating ulcerative colitis.
[0007] Furthermore, the drug uses sodium crotonate as an active ingredient and is added with pharmaceutically acceptable excipients to prepare a pharmaceutically acceptable dosage form.
[0008] Furthermore, the auxiliary material is a solid or semi-solid auxiliary material.
[0009] Furthermore, the dosage forms include tablets, capsules, and injections.
[0010] Beneficial effects:
[0011] The experimental results showed that sodium crotonate can effectively improve the DAI score, colon length and pathological tissue score of ulcerative colitis model mice, and has a significant therapeutic effect on ulcerative colitis. Therefore, sodium crotonate has the prospect of being developed into a drug for the treatment of ulcerative colitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1It is a line graph of the body weight of mice in each group.
[0013] Figure 2 The DAI scores of mice in each group are shown in Figure 2.
[0014] Figure 3 The colon length measurement results and organ index calculation results of each group of mice.
[0015] Figure 4 The colon pathological sections and histological scoring results of mice in each group; A is the colon pathological sections of mice in each group, and B is the histological scoring results of mice in each group.
[0016] Figure 5 is the content of cytokines IFN-γ, TNF-α, IL-2, IL-6, IL-9, IL-17A, IL-4 and IL-10 in the serum of each group of mice; among them, A, B, C, D, E, F, G, and H are the contents of IFN-γ, TNF-α, IL-2, IL-6, IL-9, IL-17A, IL-4 and IL-10 in the serum of different groups of mice, respectively. DETAILED DESCRIPTION
[0017] The essential contents of the present invention are described in detail below with reference to the accompanying drawings and embodiments, but the protection scope of the present invention is not limited thereto.
[0018] 1. Experimental Materials and Methods
[0019] 1. Grouping, modeling and drug administration
[0020] Materials: C57BL / 6 mice; dextran sulfate sodium (DSS); 0.5% CMC-Na solution; Crotonate sodium (Croconic Acid Disodium Salt) purchased from Shanghai Yuanye, CAS No. 14379-00-1.
[0021] C57BL / 6 mice were selected as experimental subjects and purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd. They were 7-8 weeks old and adaptively raised in the Pharmacology Laboratory of Jiangsu Provincial Hospital of Traditional Chinese Medicine for about one week. The experiment was carried out when the body weight reached about 20 g.
[0022] The mice were randomly divided into blank group (Control), model group (DSS), sodium crotonate group (NaCr) and sulfasalazine group (SASP), with 8 mice in each group.
[0023] The experimental period was 7 days. The mice in the blank group drank normal water for 7 days, and the other groups drank 3% DSS aqueous solution from the first day to the seventh day for ulcerative colitis (UC) modeling. Drug intervention began on the first day of modeling: the sodium crotonate group was gavaged with 20 mg / kg sodium crotonate, and the sulfasalazine group (positive control group) was gavaged with 200 mg / kg sulfasalazine. The solvents were all 0.5% CMC-Na solution. The blank group and the model group were gavaged with the same dose of 0.5% CMC-Na solution. The mice were killed by cervical dislocation on the 7th day of feeding.
[0024] 2. Body weight measurement
[0025] On the first day of the formal experiment, the mice were weighed at the same time every day and recorded in a table. After the experiment ended on the 7th day, all weights were sorted and made into a line graph, using weight to reflect the severity of the mice's disease.
[0026] 3. Determination of Disease Activity Index (DAI) score
[0027] During the experiment, the weight change, stool characteristics and blood in the stool of mice were recorded every day, and the disease activity index (DAI) score was determined. DAI is obtained by adding the weight loss rate score, stool characteristics score and blood in the stool score, and the score ranges from 0 to 12. The scoring criteria are as follows: 1) Weight loss rate score: no weight loss, 0 points; weight loss of 5% to 9%, 1 point; weight loss of 10% to 14%, 2 points; weight loss of 15% to 20%, 3 points; weight loss greater than 20%, 4 points. 2) Stool characteristics score: normal, 0 points; loose, 1 point; semi-formed and thin, 2 points; unformed and thin, 3 points; watery diarrhea, 4 points. 3) Stool and blood in the stool score: negative blood in the stool (-), 0 points; weak positive blood in the stool (+), 1 point; positive blood in the stool (++), 2 points; strong positive blood in the stool (+++), 3 points; blood in the stool visible to the naked eye, 4 points. After the experiment ended on the 7th day, all DAI scores were collated and made into a line graph as an indicator of the severity of the disease in mice.
[0028] 4. Determination of serum inflammatory indexes
[0029] Material: LEGENDplex TM Multi-Analyte FlowAssay Kit.
[0030] Methods: Blood was collected from the orbital venous plexus of mice on the 7th day after the experiment, and the supernatant was centrifuged and stored at -80℃ for future use to avoid repeated freezing and thawing. Serum samples were thawed on ice, and the processing steps were performed according to the instructions of the LEGENDplex multifactor kit and analyzed using a Cytoflex flow cytometer (Beckman Coulter, Krefeld, Germany). Data were analyzed using Legendplex V8.0 software (Biolegend).
[0031] 5. Colon length measurement
[0032] After the mice were killed on the 7th day, they were dissected, their livers, spleens and thymuses were weighed, and the organ index was calculated; the colon part was taken, placed on a white paper, and the length was measured with a ruler and recorded. The colon length was used as an aspect to reflect the severity of the disease.
[0033] 6. Colon pathology sections and histological scoring
[0034] Materials: 4% paraformaldehyde; EDTA; HE dye; neutral resin; xylene; ethanol
[0035] Methods: After the experimental mice were killed, the colon containing the lesion was cut to about 1 cm long and fixed in 4% paraformaldehyde, decalcified with EDTA, embedded in paraffin, sliced 4-5 μm (longitudinal section), dewaxed with conventional xylene, various levels of ethanol, and distilled water until water; HE staining. Hematoxylin stained the nucleus, and eosin stained the cytoplasm; neutral resin was used to seal the slides, and the pathological histological changes were observed under an optical microscope. The histological scoring criteria for colon sections were divided into two aspects: epithelial damage and mucosal inflammatory cell infiltration: epithelial damage was divided into 5 levels: 0, no damage; 1, a small amount of goblet cell loss; 2, a large amount of goblet cell loss; 3, a small amount of crypt disappearance and a large amount of goblet cell loss; 4, a large amount of crypt disappearance. Inflammatory infiltration was divided into 5 levels: 0, no infiltration; 1, infiltration to the bottom of the crypt; 2, infiltration to the muscularis mucosa; 3, a large amount of infiltration of the muscularis mucosa with edema; 4, infiltration to the submucosal layer. The sum of the scores of the above two parts is the histological score.
[0036] 7. Data processing
[0037] The experimental results were expressed as (Mean±SEM), and Student's t was used for comparison between two groups, and One-way ANOVA and post hoc test were used for comparison between multiple groups. *P<0.05 was statistically different, **P<0.01 was statistically significant, and ***P<0.001 was extremely statistically significant.
[0038] 2. Experimental Results
[0039] 1. Weight measurement results
[0040] The body weight of mice in each group is shown in the figure Figure 1 As shown, there was no significant change in the body weight of the mice in the blank group during the experimental period. Compared with the blank group, the body weight of the mice in the model group showed a significant downward trend during the experimental period. Compared with the model group, the weight loss trends of the mice in the sodium crotonate group and the sulfasalazine group during the experimental period were effectively controlled.
[0041] 2. Disease Activity Index (DAI) score results
[0042] The DAI scores of mice in each group are shown in Figure 2 As shown, compared with the blank group, the DAI scores of mice in the model group were significantly increased; compared with the model group, the DAI scores of mice in the sodium crotonate group and sulfasalazine group were significantly decreased.
[0043] 3. Colon length measurement results and organ index calculation results
[0044] The colon length measurement results and organ index calculation results of each group of mice are shown in Figure 3 As shown in the figure, compared with the blank group, the colon length and thymus index of the mice in the model group were significantly decreased; compared with the model group, the colon length of the mice in the sodium crotonate group and sulfasalazine group was significantly increased. Compared with the blank group, the liver index and spleen index of the mice in the model group were significantly increased; compared with the model group, the liver index and spleen index of the mice in the sodium crotonate group and sulfasalazine group were significantly decreased.
[0045] 4. Colon pathology sections and histological scoring results
[0046] The colon pathological sections and histological scores of mice in each group are shown in Figure 4 As shown, compared with the blank group, the colon of the mice in the model group showed obvious lesions and enhanced inflammatory infiltration; compared with the model group, the colon lesions of the mice in the sodium crotonate group and the sulfasalazine group were significantly alleviated, and the inflammatory infiltration was improved.
[0047] 5. Determination of serum inflammatory indexes
[0048] The levels of cytokines IFN-γ, TNF-α, IL-2, IL-6, IL-9, IL-17A, IL-4 and IL-10 in the serum of mice in each group were as shown in Figure 5 As shown in the figure, IL-4 and IL-10 belong to the anti-inflammatory factor family, and the rest are pro-inflammatory factors. Compared with the blank group, the levels of pro-inflammatory factors in the serum of mice in the model group were significantly increased, and the levels of anti-inflammatory factors were significantly decreased. Compared with the model group, the levels of pro-inflammatory factors and anti-inflammatory factors in the serum of mice in the sodium crotonate group and sulfasalazine group were adjusted to varying degrees.
[0049] In summary, sodium crotonate can effectively improve the DAI score, colon length and pathological tissue score of ulcerative colitis model mice, and has a significant therapeutic effect on ulcerative colitis.
[0050] The purpose of the above-mentioned embodiments is to specifically introduce the essential content of the present invention, but those skilled in the art should know that the protection scope of the present invention should not be limited to the specific embodiments.
Claims
1. Use of sodium crotonate for preparing a medicine for treating ulcerative colitis.
2. The use according to claim 1, wherein the drug has sodium crotonate as an active ingredient and is added with pharmaceutically acceptable excipients to prepare a pharmaceutically acceptable dosage form.
3. The use according to claim 2, characterized in that: The auxiliary material is a solid or semi-solid auxiliary material.
4. The use according to claim 2, characterized in that: The dosage forms include tablets, capsules and injections.
